This activity is supported by an independent education grant from Johnson & Johnson. This education program is only available to healthcare professionals in the USA.

Credits: AMA PRA Category 1 Credits™ (0.50.00 hours)

Type of activity: Enduring material (Infographic)

Launch date: 25 August 2026

Expiration date: 25 April 2027

Who Should Participate

This Activity is designed for healthcare professionals who are involved in the diagnosis, treatment, and ongoing management of patients with relapsed/refractory multiple myeloma (RRMM)

Faculty

Dr Ajay K. Nooka, MD, MPH, FACP

Dr Ajay K. Nooka, MD, MPH, FACP, is a Professor of Hematology and Medical Oncology at Emory University School of Medicine, where he serves as Director of the Myeloma Program and Associate Director of Clinical Research at the Winship Cancer Institute. Specializing in multiple myeloma and plasma cell disorders, his research focuses on improving risk stratification and evaluating novel therapies, including CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates. A globally recognized expert, Dr. Nooka serves on the steering committee of the Multiple Myeloma Research Consortium (MMRC) and holds editorial positions at leading journals, including Cancer and Clinical Lymphoma, Myeloma and Leukemia.

Dr Joshua Richter, MD

Dr Joshua Richter, MD is an Associate Professor of Medicine in the Division of Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai and serves as the Director of Multiple Myeloma at the Blavatnik Family Chelsea Medical Center at Mount Sinai. Specializing in multiple myeloma and related plasma cell disorders, his clinical and translational research focuses on the design and implementation of clinical trials evaluating novel therapeutics, including bispecific antibodies, CAR T-cell therapies, and innovative combination regimens. A dedicated educator and prominent voice in the hematology community, Dr. Richter frequently presents his research at major international oncology conferences and is deeply committed to optimizing treatment sequencing and side-effect management to improve patient outcomes.

Continuing Education Information

This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.

Disclosures

Dr Ajay Nooka has disclosed financial relationships within the past 24 months with the following ineligible companies: Consultant / Advisor: AstraZeneca, Blue Earth Diagnostics, GlaxoSmithKline, Janssen, KITE, ONK Therapeutics, OPNA, Pfizer, Sebia, Perspective Informatics and Premier Research. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Dr Nooka does not intend to discuss non-FDA uses of drug products and/or devices only in relation to products for which he has no financial relationships.

Dr Joshua Richter has disclosed financial relationships within the past 24 months with the following ineligible companies: Consultant / Advisor: Janssen, BMS, Pfizer, Karyopharm, Sanofi, Takeda, Genentech, Abbvie, Regeneron, Forus, Menarini, Kite/Arcellx, UB Therapeutics. Speakers bureau: Janssen, BMS, Sanofi, Adaptive Biotechnologies, Pfizer. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Dr Richter does not intend to discuss non-FDA uses of drug products and/or devices only in relation to products for which she has no financial relationships.

AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible companies.

All relevant financial relationships for anyone involved with the content of this activity have been mitigated prior to the commencement of the program.

Activity Accreditation for Health Professions

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring material a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring material a maximum of 0.5 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses & Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

System Requirements

Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program.

Unapproved and/or off-label use disclosure

AffinityCE/MedAll requires CE faculty to disclose to the participants:

• When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
• Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

CME Inquiries

For all CME policy-related inquiries, please contact us at ce@affinityced.com.

Participation Costs

There is no cost to participate in this program.

To Earn CME Credit

1. Review the program materials
2. Click the green button on the right to "Claim CME credit"
3. Complete the Post-Test; this test features real-time learning. You will receive immediate feedback and rationales explaining the correct answers as you go. The requirement is 70% accuracy.
4. Once you have successfully passed the test and completed the required CME evaluation, your certificate will be available for download and emailed to you.

Disclaimer

This activity is intended for educational purposes only and does not establish a standard of care or replace clinical judgment. Any therapeutic or diagnostic strategies discussed must be evaluated in the context of each patient’s clinical circumstances, risks, and current evidence.

Learners should consult authoritative clinical guidelines and approved product information when considering treatment decisions.

All materials are used with permission. The views expressed are those of the faculty and do not necessarily reflect those of the accredited providers, MedAll, or any supporters.

Content is accurate as of the date of release.

Estimated time for this activity: 30 minutes